SJOGRINGO Friday, 10/03/14 01:34:52 PM Re: SJOGRINGO post# 46 Post # of 93 Acorda Therapeutics. Quote: Also, Cramer checked in with Dr. Ron Cohen, the founder and CEO of Acorda Therapeutics. "In this increasingly difficult market, I think it's worth circling the wagons around secular growth companies, like the biotechs, because they're not sensitive to swings in the global economy," Cramer said. And with Acorda Therapeutics (ACOR) buying the privately held Civitas Therapeutics for $525 million, Cramer felt the company deserved a closer look. "Through the acquisition, Acorda will get a promising inhaled dry powder formulation that helps alleviate some of the symptoms of Parkinson's disease. Not only does this drug address a real unmet medical need, but it's right on the cusp of entering phase 3 trials and it could potentially do $500 million in peak sales. If this drug can get FDA approval then Civitas will look like a total steal. But if it gets bottled up because of weak phase 3 results, it might be a colossal overpay." Cramers Comments of Parkinson Never buy/sell based on my posts.My posts are opinions only.My positions are subject to change W/O notice NOTICE: NSA reportedly monitors,copies,and captures IP address of electronic communications to and from the USA.